Indaptus Therapeutics Reports Positive Decoy20 Phase 1 Trial ResultsBy topmanagerMarch 4, 20240 Indaptus Therapeutics saw a significant increase in shares, rising by 26% to $2.63 in premarket trading following the announcement of…
